Detalles de la búsqueda
1.
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
N Engl J Med
; 384(6): 512-520, 2021 02 11.
Artículo
Inglés
| MEDLINE | ID: mdl-33567191
2.
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
Br J Clin Pharmacol
; 87(12): 4670-4680, 2021 12.
Artículo
Inglés
| MEDLINE | ID: mdl-33960504
3.
Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.
Int J Clin Pharmacol Ther
; 52(10): 889-99, 2014 Oct.
Artículo
Inglés
| MEDLINE | ID: mdl-25138682
4.
Contact Sensitization and Phototoxic and Photoallergic Potential of Tirbanibulin 1% Ointment in Healthy Volunteers.
JID Innov
; 3(2): 100170, 2023 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-36699198
5.
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
J Clin Oncol
; 41(1): 65-74, 2023 01 01.
Artículo
Inglés
| MEDLINE | ID: mdl-35858154
6.
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
Ther Adv Med Oncol
; 15: 17588359231183680, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-37492633
7.
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.
Eur J Clin Pharmacol
; 68(3): 249-58, 2012 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-21935705
8.
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
Eur J Clin Pharmacol
; 68(11): 1509-16, 2012 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-22476387
9.
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.
Eur J Clin Pharmacol
; 68(11): 1501-8, 2012 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-22527342
10.
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.
Eur J Clin Pharmacol
; 68(7): 1049-56, 2012 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-22315147
11.
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
Eur J Clin Pharmacol
; 68(3): 291-300, 2012 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-21969227
12.
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results.
Pharmaceutics
; 14(10)2022 Oct 11.
Artículo
Inglés
| MEDLINE | ID: mdl-36297594
13.
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
Cancer Invest
; 29(9): 617-25, 2011 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-22011284
14.
Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C.
Eur J Clin Pharmacol
; 67(6): 591-9, 2011 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-21161196
15.
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.
Eur J Clin Pharmacol
; 67(5): 483-92, 2011 May.
Artículo
Inglés
| MEDLINE | ID: mdl-21120461
16.
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Clin Pharmacokinet
; 59(8): 949-965, 2020 08.
Artículo
Inglés
| MEDLINE | ID: mdl-32337660
17.
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
Clin Pharmacol Drug Dev
; 8(3): 314-325, 2019 04.
Artículo
Inglés
| MEDLINE | ID: mdl-29786959
18.
Reply to Z.R. McCaw et al.
J Clin Oncol
; 41(6): 1323-1324, 2023 02 20.
Artículo
Inglés
| MEDLINE | ID: mdl-36346667
19.
No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 7(2): 143-150, 2018 02.
Artículo
Inglés
| MEDLINE | ID: mdl-28403576
20.
A Phase 1, Randomized, Placebo- and Active-Controlled Crossover Study to Determine the Effect of Single-Dose Ertugliflozin on QTc Interval in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 7(5): 513-523, 2018 06.
Artículo
Inglés
| MEDLINE | ID: mdl-29346837